Reviewing Coeptis Therapeutics (ZSQR) and The Competition

Coeptis Therapeutics (NASDAQ:ZSQR) is one of 954 public companies in the “Software” industry, but how does it contrast to its rivals? We will compare Coeptis Therapeutics to related companies based on the strength of its earnings, institutional ownership, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for Coeptis Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1	0	0	0	1.00
Coeptis Therapeutics Competitors	5717	21424	44693	1492	2.57

As a group, “Software” companies have a potential upside of 27.89%. Given Coeptis Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts plainly believe Coeptis Therapeutics has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of shares of all “Software” companies are owned by institutional investors. 24.2% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 19.8% of shares of all “Software” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Coeptis Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	$1.36 million	-$11.92 million	-2.26
Coeptis Therapeutics Competitors	$1.84 billion	$385.92 million	110.50

Coeptis Therapeutics’ rivals have higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Coeptis Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ rivals have a beta of 1.26, suggesting that their average stock price is 26% more volatile than the S&P 500.

Profitability

This table compares Coeptis Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Coeptis Therapeutics Competitors	-620.53%	20.98%	-8.95%

Summary

Coeptis Therapeutics rivals beat Coeptis Therapeutics on 12 of the 13 factors compared.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.